Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study

Despite progress in treating homozygous familial hypercholesterolemia, most patients do not achieve low-density lipoprotein cholesterol (LDL-C) targets. This study examined efficacy and safety of the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, alirocumab, in pediatric patients (...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruckert, Eric, Caprio, Sonia, Wiegman, Albert, Charng, Min-Ji, Zárate-Morales, Cézar A., Baccara-Dinet, Marie T., Manvelian, Garen, Ourliac, Anne, Scemama, Michel, Daniels, Stephen R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical and Population Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750107/
https://www.ncbi.nlm.nih.gov/pubmed/36325897
http://dx.doi.org/10.1161/ATVBAHA.122.317793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750107/
https://www.ncbi.nlm.nih.gov/pubmed/36325897
http://dx.doi.org/10.1161/ATVBAHA.122.317793

Ejemplares similares